Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage Ⅱ-Ⅲ NSCLC

>A phase 3 clinical study (NEOTORCH) of toripalimab in combination with platinum-containing doublet chemotherapy as perioperative treatment for resectable stage II-III NSCLC patients has finished its final analysis.

Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma

>The NDA for toripalimab in combination with disitamab vedotin for patients with HER2-expressing locally advanced or metastatic UC was approved by the NMPA. With this latest approval, toripalimab injection now has 13 approved indications in the Chinese Mainland.

Junshi Biosciences Announces NMPA Acceptance of New Drug Applications for Toripalimab Injection (Subcutaneous) Across 12 Indications

>The NDAs for toripalimab injection (subcutaneous injection [code: JS001sc]), for 12 indications in the treatment of tumors has been accepted by the NMPA. JS001sc is the first domestic anti-PD-1 monoclonal antibody in a subcutaneous formulation to enter the marketing application stage.

Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis

>The NDA for the company’s product, roconkibart injection (anti-IL-17A mAb, product code: JS005), for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy has been accepted by the NMPA